JNJ70218902-TMEFF2-hIgG4-S228P is a bispecific antibody that engages TMEFF2-expressing tumor cells and CD3 on T cells causing exposure dependent pro-inflammatory responses and target tumor cell lysis and promote T cell-mediated killing of tumor cells.
Specifications
Catalog Number:
KB-1055
Antibodies Name:
JNJ70218902-TMEFF2-hIgG4-S228P
Host Cell Line:
EXPI-CHO
Target:
TMEFF2
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA
Characterization
Application
References
1.Cassandra Lowenstein, Subhasree Basu,?Joshua Rusbuldt, et al. 1360?Pharmacodynamics of JNJ-70218902, a TMEFF2¨GCD3 bispecific antibody, in cynomolgus monkey. Journal for ImmunoTherapy of Cancer?2022; 10: doi:?10.1136/jitc-2022-SITC2022.1360.
2.Subhasree Basu, Mike Russell, Katrin Sproesser, et al. Abstract LB087:Characterization of JNJ-70218902, a TMEFF2xCD3 bispecific antibody, in prostate cancer models. POSTER PRESENTATIONS-LATE-BREAKING ABSTRACTS, JUNE 15 2022.
